Ask AI
BsAbs in RR FL

CE / CME

Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma: Efficacy, Toxicities, and Practical Implementation

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: February 03, 2026

Expiration: August 02, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Falchi L, Franck Morschhauser, Linton K, et al. EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R 2) vs R 2 alone in patients with relapsed or refractory follicular lymphoma. Blood. 2023;142(suppl 1):3053.
  2. Mosunetuzumab-axgb [prescribing information]. San Francisco, CA: Genentech, Inc; 2025.
  3. Epcoritamab-bysp [prescribing information]. Plainsboro, NJ: Genmab; 2025.
  4. Assouline S, Bartlett N, Sehn L, et al. Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study. Blood. 2025;146:(Supplement 1):5353.
  5. Sehn LH, Bartlett NL, Matasar MJ, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. 2025;145:708-719.
  6. Shadman M, Batlett NL, Matasar M, et al. Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study. Presented at: 2024 American Society of Hematology Annual Meeting. Abstract 4407.
  7. Cheah C, Bartlett NL, Matasar M, et al. Mosunetuzumab demonstrates durable clinical benefit in patients (pts) with complete response (cr) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL). EHA Library. 2025;4160289:PF883.
  8. Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:E593-E605.
  9. Kim TM, Taszner M, Novelli S, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024;35:1039-1047.
  10. Bisneto JV, Jagadeesh D, Stevens D, et al. Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study. Blood. 2025;146:(Supplement 1):3588.
  11. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055-1065.
  12. Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143:1565-1575.
  13. Hou J, Kim TM, Cho S, et al. Three-year follow-up of the phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL). Blood. 2025;146(suppl 1):1005.
  14. Flinn IW, Burke JM, Sharman JP, et al. Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study. Presented at: 2025 American Society of Clinical Oncology Annual Meeting 2025. Abstract 7014.
  15. Falchi L, Sureda A, Sirpa Leppä, et al. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025;146:2629-2640.
  16. Vitolo U, Norasetthada L, Jo JC, et al. Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): first results from part 1 (safety lead-in) of the phase 3 OLYMPIA-5 study. Presented at: 2025 American Society of Hematology Annual Meeting; December 6-9, 2025. Abstract 5381.
  17. Hambleton H, Cheah CY. The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma. Expert Opin Investig Drugs. 2025;34:245-252.
  18. Kim WS, Kim TM, Cho S, et al. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025;6:528-539.
  19. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625-638.